15.2 Acute Decompensated Heart Failure & Cardiogenic Shock

Stevenson Hemodynamic Classification & Clinical Phenotyping

Acute decompensated heart failure (ADHF) is a heterogeneous clinical syndrome characterized by the sudden or gradual worsening of heart failure signs and symptoms requiring emergent medical intervention. Bedside hemodynamic phenotyping is guided by the Stevenson Classification, which stratifies patients into four distinct quadrants based on the assessment of congestion ("Wet" vs "Dry") and perfusion ("Warm" vs "Cold").

                         STEVENSON HEMODYNAMIC 2x2 MATRIX
                         
                                CONGESTION (PCWP >18 mmHg)
                         Orthopnea, JVD, S3, Crackles, Edema
                                        
                         DRY (Absent)           WET (Present)
                   ┌──────────────────────┬──────────────────────┐
     WARM (Normal) │      PROFILE A       │      PROFILE B       │
     Adequate      │    "Warm & Dry"      │    "Warm & Wet"      │
     Perfusion     │ • Compensated HF     │ • ~80% of ADHF       │
     CI >2.2       │ • Outpatient medical │ • Congested, perfused│
                   │   optimization       │ • IV Loop Diuretics  │
                   │                      │   + IV Vasodilators  │
PERFUSION          ├──────────────────────┼──────────────────────┤
                   │      PROFILE L       │      PROFILE C       │
     COLD (Low)    │    "Cold & Dry"      │    "Cold & Wet"      │
     Hypoperfusion │ • Dehydration /      │ • CARDIOGENIC SHOCK  │
     CI <2.2       │   Overdiuresis       │ • Mortality 30-50%   │
     Lactate >2    │ • Cautious fluid     │ • Vasopressors &     │
                   │   challenge (250 mL) │   Inotropes (Norepi, │
                   │                      │   Dobutamine, MCS)   │
                   └──────────────────────┴──────────────────────┘

Clinical Markers of Congestion ("Wet")

Reflects elevated left ventricular filling pressures (Pulmonary Capillary Wedge Pressure [PCWP] >18 mm Hg) and central venous congestion (Central Venous Pressure [CVP] >10 mm Hg):

• Left-Sided Congestion: Orthopnea (quantified by number of pillows required), paroxysmal nocturnal dyspnea (PND), tachypnea, bilateral inspiratory bibasilar crackles (rales), and an S3 gallop (pathognomonic for rapid deceleration of blood into a noncompliant, dilated ventricle).
• Right-Sided Congestion: Jugular Venous Distention (JVD >8 cm H2O at 45°), positive hepatojugular reflux, hepatomegaly, ascites, and bilateral dependent peripheral pitting edema.

Clinical Markers of Hypoperfusion ("Cold")

Reflects a depressed cardiac index (<2.2 L/min/m²) and systemic hypoperfusion:

• Physical Exam: Cold, clammy extremities, pale or mottled knees, narrow pulse pressure (proportional pulse pressure [SBP - DBP] / SBP <25%), and delayed capillary refill.
• End-Organ Dysfunction: Acute altered sensorium (cerebral hypoperfusion), oliguria (<0.5 mL/kg/h), prerenal azotemia (disproportionate rise in Blood Urea Nitrogen with BUN/Creatinine ratio >20:1), and lactic acidosis (arterial/venous lactate >2.0 mmol/L).

---

Diagnostic Evaluation & Biomarker Interpretation

B-Type Natriuretic Peptides (BNP & NT-proBNP)

B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are cleaved from proBNP in equal amounts and secreted by ventricular cardiomyocytes in direct response to increased myocardial wall stretch and diastolic transmural wall tension.

Exclusion (Rule-Out) Cutoffs (High Sensitivity / NPV >95%)

• BNP <100 pg/mL
• NT-proBNP <300 pg/mL Levels below these thresholds make acute decompensated heart failure highly improbable and mandate an investigation for non-cardiac causes of dyspnea (COPD exacerbation, asthma, pulmonary embolism, pneumonia).

Age-Stratified "Rule-In" Diagnostic Cutoffs (ICON Study)

Because renal clearance declines and vascular stiffness increases with age, NT-proBNP requires age-stratified cutoffs to optimize specificity:

• Age <50 years: NT-proBNP >450 pg/mL
• Age 50 to 75 years: NT-proBNP >900 pg/mL
• Age >75 years: NT-proBNP >1,800 pg/mL

Critical Confounders and Clinical Caveats

• OBESITY CAVEAT (The Low BNP Paradox): In patients who are overweight or obese (BMI ≥30 kg/m²), circulating BNP and NT-proBNP levels are paradoxically depressed by up to 50%. This occurs due to increased expression of natriuretic peptide clearance receptors (NPR-C) on adipocytes, blunted release from pericardial fat, and altered neurohormonal clearance. Clinicians must lower diagnostic rule-in thresholds by 50% (e.g., BNP cutoff ≥50 pg/mL) in obese individuals to avoid missing severe pulmonary congestion.
• RENAL DYSFUNCTION: NT-proBNP is cleared 100% via passive renal excretion, whereas BNP is cleared by both renal excretion and enzymatic degradation via neprilysin. In chronic kidney disease (serum creatinine >2.0 mg/dL or eGFR <60 mL/min), NT-proBNP accumulates markedly; an adjusted rule-in cutoff of NT-proBNP >1,200 pg/mL is recommended.
• THE ARNI / SACUBITRIL PEARL: Sacubitril (the neprilysin inhibitor component of Sacubitril/Valsartan [Entresto]) blocks the neutral endopeptidase neprilysin, which degrades BNP. Consequently, treatment with sacubitril leads to an artifactual increase in serum BNP levels that does not reflect clinical worsening. In contrast, NT-proBNP is NOT a substrate for neprilysin; NT-proBNP levels decrease in parallel with clinical improvement and must be used exclusively to assess heart failure status in patients taking an ARNI.

Point-of-Care Ultrasound (POCUS)

POCUS provides immediate, non-invasive assessment of cardiopulmonary hemodynamics:

• Lung Ultrasound (LUS): Identifies B-lines ("lung rockets")—vertical, hyperechoic, laser-like reverberation artifacts arising from the pleural line that extend to the bottom of the screen without fading and move with lung sliding. The presence of ≥3 B-lines per intercostal space in ≥2 bilateral zones demonstrates a sensitivity of 94% and specificity of 92% for cardiogenic pulmonary edema, significantly outperforming traditional chest radiography.
• Inferior Vena Cava (IVC) Ultrasound: A plethoric, dilated IVC (>2.1 cm) with <50% inspiratory collapse during a spontaneous sniff indicates elevated right atrial pressure (>15 mm Hg) and systemic venous volume overload.

Chest Radiography (CXR)

Radiographic findings correlate sequentially with pulmonary capillary wedge pressure:

1. Cephalization of Pulmonary Vessels (PCWP 13–18 mm Hg): Upper lobe pulmonary veins dilate to equal or exceed lower lobe vessels due to redistribution of blood flow.
2. Interstitial Pulmonary Edema (PCWP 18–25 mm Hg): Characterized by Kerley B lines (thin, horizontal, 1–2 cm linear densities at the lateral lung bases perpendicular to the pleura, representing fluid accumulation in interlobular septa), peribronchial cuffing, and loss of distinct vascular margins.
3. Alveolar Pulmonary Edema (PCWP >25 mm Hg): Bilateral, fluffy, confluent perihilar alveolar opacities classically described as a "bat-wing" or "butterfly" pattern, sparing the peripheral lung cortex.
4. Associated Features: Cardiomegaly (cardiothoracic ratio >0.5 on PA film) and blunting of costophrenic angles indicative of transudative pleural effusions (bilateral or right-sided > left-sided).

---

Acute Management of Warm & Wet Heart Failure (Profile B)

Profile B ("Warm and Wet") accounts for approximately 80% of hospital presentations for ADHF. Therapy focuses on rapid decongestion through preload reduction and diuresis without compromising systemic renal perfusion.

Step 1: Intravenous Loop Diuretic Therapy

Loop diuretics (furosemide, bumetanide, torsemide) act on the Na+-K+-2Cl- cotransporter in the thick ascending limb of the Henle loop, inducing rapid natriuresis and diuresis.

• Dosing Strategy (The DOSE Trial Protocol):
  • Loop-Naive Patients: Initiate intravenous furosemide 20 to 40 mg IV bolus (or bumetanide 1 mg IV, or torsemide 20 mg IV).
  • Chronic Oral Loop Diuretic Therapy: Administer an initial IV bolus dose that is 1.0 to 2.5 times the patient's total daily home oral dose in IV milligrams. For example, a patient prescribed furosemide 40 mg orally daily should receive 40 to 80 mg IV furosemide as the initial bolus. (Remember that oral furosemide has an average bioavailability of ~50%; therefore, 40 mg IV furosemide represents twice their home oral bioavailable dose).
  • Bolus vs Continuous Infusion: The landmark DOSE trial established that intermittent bolus dosing every 12 hours and continuous infusion achieve identical clinical efficacy; however, high-dose strategies (2.5x home dose) produce more rapid dyspnea relief and fluid loss without increasing 60-day adverse outcomes.
• Diuretic Response Assessment & Titration:
  • Check a spot urine sodium at 2 hours post-diuretic (target >50 to 70 mEq/L) or monitor hourly urine output (target >100 to 150 mL/h over the first 6 hours).
  • If the diuretic response is inadequate, double the IV loop diuretic dose up to maximum single doses (e.g., furosemide 160–200 mg IV).
• Sequential Nephron Blockade: In patients with refractory diuretic resistance (often caused by compensatory hypertrophy of distal convoluted tubule cells), add an oral thiazide diuretic—such as metolazone 2.5 to 5 mg PO administered 30 minutes prior to the loop diuretic, or IV chlorothiazide 500 mg—to achieve synergistic dual-nephron sodium blockade.

Step 2: Intravenous Vasodilator Therapy

Vasodilators rapidly unload the failing left ventricle, reducing myocardial wall stress and acute dyspnea. They are particularly indicated in patients with hypertensive acute pulmonary edema (SBP >140 mm Hg) or "flash" pulmonary edema.

• Sublingual Nitroglycerin: Administer 0.4 mg sublingually every 5 minutes while obtaining IV access.
• Intravenous Nitroglycerin: Initiate at 10 to 20 mcg/min, titrating rapidly by 10 to 20 mcg/min every 5 minutes up to 100 to 200 mcg/min. At low-to-moderate doses (<100 mcg/min), nitroglycerin produces selective venodilation, reducing preload and left ventricular end-diastolic pressure. At higher doses (>100 mcg/min), it induces modest arteriolar dilation, reducing afterload.
• Intravenous Sodium Nitroprusside: Potent, balanced arterial and venous vasodilator. Initiate at 0.3 mcg/kg/min, titrating up to 2.0 mcg/kg/min. Indicated for acute severe hypertensive crises, severe acute aortic regurgitation, or acute mitral regurgitation. Requires continuous intra-arterial blood pressure monitoring. Carries a risk of cyanide and thiocyanate toxicity with prolonged infusions (>48 hours), high doses, or renal impairment.

Step 3: Non-Invasive Positive Pressure Ventilation (NIPPV)

In patients with acute cardiogenic pulmonary edema who present with respiratory distress (tachypnea >25 breaths/min, SpO2 <90%, accessory muscle use), NIPPV should be applied immediately:

• Modality: Continuous Positive Airway Pressure (CPAP 5 to 10 cm H2O) or Bilevel Positive Airway Pressure (BiPAP: IPAP 10–15 cm H2O, EPAP 4–6 cm H2O).
• Physiologic Mechanisms:
  1. Preload Reduction: Positive intrathoracic pressure decreases systemic venous return to the right heart.
  2. Afterload Reduction: Positive intrathoracic pressure decreases left ventricular transmural pressure gradient, lowering LV afterload and systolic myocardial workload.
  3. Alveolar Recruitment: Opens fluid-filled, atelectatic alveoli, improving functional residual capacity, clearing alveolar fluid back into the interstitial space, and reversing ventilation-perfusion mismatch.
• Clinical Outcomes: Multiple randomized controlled trials have demonstrated that NIPPV reduces the endotracheal intubation rate by ~60% and produces a statistically significant reduction in in-hospital mortality compared to oxygen therapy alone.

Step 4: Beta-Blocker Management Rules in Acute Decompensation

The handling of chronic beta-blockers in acute decompensation is a high-yield board topic:

• Rule 1: CONTINUE Chronic Beta-Blockers During Mild-to-Moderate Decompensation: If the patient was previously stable on an evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol) and presents with congestion without cardiogenic shock or profound bradycardia, continue their chronic beta-blocker therapy (maintaining full dose or temporarily reducing by 50%). Abrupt discontinuation triggers an acute rebound catecholamine surge, worsens tachycardia, and is associated with increased in-hospital and 60-day mortality.
• Rule 2: DISCONTINUE Chronic Beta-Blockers in Cardiogenic Shock: If the patient exhibits signs of cardiogenic shock (Profile C: hypotension, cool extremities, lactic acidosis, requirement for inotropes), beta-blockers must be held or immediately discontinued due to their negative inotropic effects.
• Rule 3: NEVER Initiate or Up-Titrate Beta-Blockers in Acute Decompensation: Beta-blockers must NEVER be started or increased in dose in a congested, acutely decompensated patient. Beta-blockers should be initiated only when the patient has achieved complete euvolemia (Profile A), has been successfully weaned from IV diuretics and vasodilators, and is clinically stable prior to hospital discharge.

---

Cardiogenic Shock: Hemodynamics, Vasoactive Support & Mechanical Devices

Cardiogenic shock (Stevenson Profile C: "Cold and Wet") is a state of critical end-organ hypoperfusion caused by primary cardiac pump failure. It carries an in-hospital mortality rate of 30% to 50%.

Clinical and Hemodynamic Diagnostic Criteria

• Persistent Hypotension: Systolic BP <90 mm Hg or mean arterial pressure (MAP) drop >30 mm Hg from baseline for >30 minutes.
• Depressed Cardiac Index: CI <2.2 L/min/m² (and typically <1.8 L/min/m² without support).
• Elevated Filling Pressures: Pulmonary Capillary Wedge Pressure (PCWP) >15 mm Hg (typically >18 to 20 mm Hg).
• Overt Hypoperfusion: Oliguria (<0.5 mL/kg/h), cool and clammy skin, mottled knees, altered mental status, and arterial serum lactate >2.0 mmol/L.

Vasoactive Support: Vasopressors & Inotropes

                         VASOPRESSOR & INOTROPIC ESCALATION
                         
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │ FIRST-LINE VASOPRESSOR: NOREPINEPHRINE (0.02 to 1.0 mcg/kg/min)                        │
  │ • Potent Alpha-1 vasoconstrictor + modest Beta-1 inotrope                              │
  │ • SOAP II Trial: Superior to dopamine (lower mortality, 50% fewer arrhythmias)         │
  │ • Restores coronary and systemic perfusion pressure (Goal: MAP ≥65 mm Hg)              │
  └───────────────────────────────────────────┬────────────────────────────────────────────┘
                                              │
                                              ▼ (Once MAP ≥65 mm Hg stabilized)
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │ INOTROPIC SUPPORT: AUGMENT FORWARD CARDIAC OUTPUT & STROKE VOLUME                      │
  ├───────────────────────────────────────────┬────────────────────────────────────────────┤
  │ DOBUTAMINE (2.5 to 20 mcg/kg/min)         │ MILRINONE (0.125 to 0.75 mcg/kg/min)       │
  │ • Synthetic Beta-1 > Beta-2 agonist       │ • Phosphodiesterase-3 (PDE-3) Inhibitor    │
  │ • Increases cAMP, contractility & SV      │ • Prevents cAMP degradation (Inodilator)   │
  │ • Causes mild peripheral vasodilation     │ • Decreases afterload & pulmonary vascular │
  │ • Adverse: Tachyarrhythmias, angina       │   resistance; unloads RV and LV            │
  │ • Ineffective if heavy beta-blockade      │ • Ideal for patients on chronic beta-block │
  │                                           │ • Renal clearance; long t1/2; hypotension  │
  └───────────────────────────────────────────┴────────────────────────────────────────────┘

• Vasopressor of Choice: Norepinephrine:
  • In the landmark SOAP II trial (Sepsis Occurrence in Acutely Ill Patients), norepinephrine was proven to be significantly superior to dopamine in patients with cardiogenic shock. Dopamine was associated with a statistically significant increase in mortality and a twofold increase in serious tachyarrhythmias. Dopamine is no longer recommended as first-line therapy.
  • Norepinephrine provides potent alpha-1-mediated vasoconstriction that restores systemic vascular resistance and coronary perfusion pressure, accompanied by modest beta-1-adrenergic inotropic support.
• Inotropic Support: Dobutamine vs Milrinone:
  • Dobutamine: First-line inotrope when blood pressure is borderline. Acts directly on beta-1 receptors to increase contractility and stroke volume. May trigger sinus tachycardia and ventricular ectopy.
  • Milrinone: Second-line or preferred agent in patients chronically treated with beta-blockers (milrinone acts downstream of the beta-receptor by inhibiting PDE-3). Because it induces potent pulmonary and systemic vasodilation ("inodilator"), it can cause severe hypotension; avoid loading boluses in acute shock. Milrinone is cleared 100% by the kidneys and requires dose reduction in renal failure.

Mechanical Circulatory Support (MCS)

When pharmacological therapy fails to restore tissue perfusion, temporary mechanical circulatory support must be deployed rapidly:

1. Intra-Aortic Balloon Pump (IABP): Positioned in the descending aorta distal to the left subclavian artery. Inflates during diastole (augmenting coronary artery perfusion) and deflates immediately prior to systole (vacuum effect reducing LV afterload and stroke work). Provides modest cardiac output augmentation (~0.5 L/min). Contraindicated in severe aortic insufficiency or aortic dissection.
2. Microaxial Left Ventricular Assist Device (Impella): Catheter-mounted axial flow Archimedes screw pump inserted retrogradely across the aortic valve into the left ventricle. Continuously pulls blood directly from the LV cavity and expels it into the ascending aorta, delivering 2.5 to 5.0 L/min of non-pulsatile forward flow. Directly unloads the left ventricle, reduces PCWP, and markedly decreases myocardial oxygen consumption.
3. Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO): Drains desaturated venous blood from the right atrium or femoral vein, pumps it through an external membrane oxygenator, and returns pressurized, oxygenated blood into the femoral artery or ascending aorta. Provides complete biventricular and respiratory circulatory support, but increases left ventricular afterload (frequently paired with an Impella [ECPELLA] to decompress the left ventricle).